Detalhe da pesquisa
1.
Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy.
Br J Cancer
; 116(9): 1166-1176, 2017 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28334731
2.
Discovery of an In Vivo Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones.
J Med Chem
; 66(8): 5892-5906, 2023 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37026591
3.
Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 In Vivo.
J Med Chem
; 65(12): 8191-8207, 2022 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35653645
4.
The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Clin Cancer Res
; 13(23): 7191-8, 2007 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18056200
5.
Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts.
Assay Drug Dev Technol
; 5(3): 391-401, 2007 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17638539
6.
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Oncotarget
; 7(3): 2329-42, 2016 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26295308
7.
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).
J Med Chem
; 59(11): 5221-37, 2016 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27167172
8.
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.
Clin Cancer Res
; 18(20): 5650-61, 2012 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22929806
9.
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors.
J Med Chem
; 55(22): 10229-40, 2012 Nov 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-23082860
10.
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.
Clin Cancer Res
; 18(14): 3912-23, 2012 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22781553